Maternal serum screening marker levels in twin pregnancies affected by gestational diabetes.


Journal

Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213

Informations de publication

Date de publication:
03 2019
Historique:
received: 06 05 2018
accepted: 07 12 2018
pubmed: 21 12 2018
medline: 7 3 2020
entrez: 21 12 2018
Statut: ppublish

Résumé

To investigate the levels of maternal serum screening markers in the first and second trimester twin pregnancies, which subsequently developed gestational diabetes mellitus (GDM). 145 twin pregnancies were recruited in the first trimester. Stored blood samples were retrospectively tested for pregnancy-associated plasma protein (PAPP)-A, human chorionic gonadotrophin (hCG), placental growth factor (PlGF), placental protein (PP)13, α-fetoprotein (aFP) and inhibin A. Values were expressed in multiples of the gestation-specific median (MoMs) in singletons, adjusted for maternal weight and parity, as appropriate. Twenty samples of first and second trimester were available from 11 twins who subsequently developed GDM and 219 samples from unaffected twins. The median PAPP-A level in the affected twins was 3.61 MoM compared with 2.46 MoM in unaffected twins (P < 0.001, Wilcoxon rank sum test, two tailed); significant results were found in both trimesters. The median PP13 was also increased but to a lesser extent. It was only statistically significant overall (P < 0.05) and in second trimester samples (P < 0.02). No other marker differed significantly. Logistic regression found that combining PAPP-A and maternal weight had a 55% detection rate for a 10% false-positive rate. Early prenatal marker evaluation in twin pregnancies can be also useful for predicting the risk for developing GDM and should be further investigated.

Identifiants

pubmed: 30569341
doi: 10.1007/s00404-018-5010-3
pii: 10.1007/s00404-018-5010-3
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

655-663

Subventions

Organisme : aspre
ID : FP7 # 601852
Pays : International

Auteurs

Ron Maymon (R)

The Yitzhak Shamir Medical Center (Formerly Assaf Harofeh Medical Center), Institute of Ultrasound, Zerifin, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Hamutal Meiri (H)

ASPRE Project, Telemarpe Ltd, Tel Aviv, Israel.
Hy-Laboratories Ltd, Rehovot, Israel.

Ran Svirski (R)

The Yitzhak Shamir Medical Center (Formerly Assaf Harofeh Medical Center), Institute of Ultrasound, Zerifin, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Eran Weiner (E)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. masolbarak@gmail.com.
Wolfson Medical Center, Holon, Israel. masolbarak@gmail.com.

Howard Cuckle (H)

Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH